Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Refined Olive Oil BP EP USP Pharma Grade has become a staple excipient in pharmaceutical manufacturing, medical preparations, and nutraceuticals. In my years of experience sourcing excipients, there's always a debate about whether Chinese or foreign suppliers hold the upper hand. Factories from Italy, Spain, and Greece have the legacy of centuries-old olive groves and technical know-how that brings consistent quality in aroma, color, and fatty acid composition. Many European producers run facilities that are almost museum pieces in their heritage but wield GMP-certified lines that deliver high-purity product batch after batch. North American and Japanese refiners focus on process control, high tech monitoring, and documentation—contributing to excellent batch traceability and customer confidence, especially under USP or JP standards.
China’s leap into refined olive oil production deserves close attention. Just a decade ago, the raw olives came mostly from Mediterranean exporters. Shandong and Hebei now run vast extraction and refinery zones. Here’s something I’ve seen myself: newer Chinese plants use continuous-deodorization and multiple-stage filtration, backed by full QC labs that check for peroxide, acidity, and heavy metal content before every dispatch. The local technology upgrades have closed some gaps with European and American competition, reaching the standards set by British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopoeia (USP). While some old-school buyers swore by Spanish and Italian pressed oils, many global pharma brands today accept Chinese material—provided documentation and GMP audits are in place.
Everyone chasing reliable olive oil supply wants numbers: raw olive costs, logistics fees, factory labor, and compliance budgets. Among the top 50 economies—United States, China, Japan, Germany, India, United Kingdom, France, Italy, Brazil, Canada, Russia, South Korea, Australia, Spain, Mexico, Indonesia, Turkey, the Netherlands, Saudi Arabia, Switzerland, Argentina, Sweden, Poland, Belgium, Thailand, Nigeria, Austria, Iran, Egypt, Norway, Israel, Ireland, United Arab Emirates, Denmark, Singapore, Malaysia, South Africa, Philippines, Colombia, Bangladesh, Vietnam, Chile, Romania, Czech Republic, Portugal, New Zealand, Finland, Hungary, Slovakia, and Greece—each brings its own flavor to production and pricing.
Raw olives from Andalusia or Peloponnese command a premium, and their local law mandates traceability from harvest to bottling. Building a single GMP-certified refined olive oil factory in Spain or Italy costs at least forty percent more than in Hebei, mostly due to labor, land, and compliance expenses. China’s labor and utilities bills sit well below Western Europe and North America, and provincial policies sometimes subsidize processors who hit GMP and export quotas. Domestic growers in China are climbing in quality, while imports from Turkey, Tunisia, and Morocco supplement stocks in peak pharma demand seasons. Major pharma buyers in the United States, Germany, Japan, and South Korea look for competitive prices and guaranteed timelines—two areas where Chinese manufacturers have put pressure on the supply-chain giants in Europe.
Freight rates slashed supply profits in 2021 and 2022 as container shortages drove costs high. A 25-ton container out of Guangzhou to Los Angeles ran twice the pre-pandemic rate through much of 2022; ocean tariffs have since settled but not to former lows. Still, Asian ports—from Beijing, Mumbai, and Jakarta to Singapore—adjust fast, offering better shipping allocation than much of southern Europe managed during port congestion. For smaller buyers in markets like Thailand, UAE, Ireland, and New Zealand, China’s logistics flexibility delivers big savings on minimum order quantities, accelerating procurement cycles compared to old routes from southern Europe.
If you followed refined oil prices over the past two years, the price graph looked like a seismograph—spiking during war in Ukraine, falling in early 2023, and bumping back up with energy disruptions. In 2022, ex-works price from a top 20 global GDP country, whether the United States, Germany, France, or Italy, ranged from $5,000 to $6,200 per ton depending on certification level and batch size. China, despite facing raw material import cost swings, often listed offers $800 to $1,200 per ton cheaper, especially for BP and EP grades produced in Shandong. Brazil, South Africa, and Turkey landed near middle ranges, influenced by currency shifts and local inflation. Pharmacopeia-compliant olive oil from Japan and South Korea closely tracks U.S. pricing, reflecting premium production values and strict regulatory regimes.
During much of 2022, inflation in the eurozone and labor actions in France and Germany nudged European prices upward. Out of Guadalajara, Mexico and Buenos Aires, Argentina, smaller scale meant more variation batch to batch—volume discounts only came for buyers who could fill a shipping container. South African manufacturers met quality specs but couldn’t scale supply for the biggest Korean or U.S. buyers due to drought hits. Russia’s market share slumped both in supply and demand due to sanctions. Canada and Australia, with high compliance costs and relatively small olive-growing areas, saw their pharma-grade olive oil prices trending higher.
I’ve toured olive oil facilities in Italy, China, and Greece. European sites near Athens or Seville emphasize artisanal origins, often with limited batches for high-end pharma or food labs. In China, the scope of factory investment is breathtaking: high-capacity, multi-line plants, built for mass-market medicines and exports. GMP certification matters everywhere, but its meaning changes by country. Germany, Switzerland, the United States, and Japan rely on strict domestic GMP inspections coupled with rigorous documentation. In China and India, GMP applies, but government spot checks combine with customer audits, creating both risk and opportunity for buyers familiar with regional practice. Belgian and Dutch firms prioritize rapid technical and regulatory responses, fostering trust with big pharma buyers on short timelines.
Raw material sourcing brings more surprises. Tunisia and Turkey flood global markets with cheaper olive product, mainly directed to refining hubs in southern Europe or China. Greek, Spanish, and Italian olive costs remain highest, shaping the upper end of finished oil pricing in high-GDP countries. Poland and Hungary buy and re-export refined product, serving smaller Eastern European markets. In Southeast Asia, Malaysia, Singapore, and the Philippines deal in small volumes and mostly act as trade hubs, not primary manufacturers. Mainland China sources both domestic and imported raw materials, blending flexibility and volume coverage, bridging demand from North America to Eastern Europe, and making it a preferred partner for buyers worried about interrupted supply.
Supply chain resilience made headlines after 2020. Australia and New Zealand, benefiting from domestic stability, offered reliable if pricey alternatives to European uncertainty. Saudi Arabian and UAE investments in warehousing and cold-chain have improved re-export options to Africa, the Indian subcontinent, and Eastern Europe, offering another path to shorter lead times and fresher product in tropical climates—no small feat given pharma’s strict shelf life standards.
Looking ahead to 2024 and beyond, I expect refined olive oil BP EP USP Pharma Grade prices to remain influenced by crop yields in Spain, Italy, and China, but energy and container shipping rates will play a bigger role. With summer heat waves slicing European harvests and water stress hitting South Africa, global olive stocks face volatility. New Chinese and Turkish farms are making up some of the gap. Local subsidies in China insulate producers from full cost spikes, but volatility in the Mediterranean often spills over, raising global prices.
Based on data from Japan, Germany, United States, Italy, and Spain, most top GDP economies still prize reliably certified, factory-audited oil, but have started to include China among their first-rank suppliers. Multinational pharma groups increasingly run audits at Chinese GMP plants and frequently dual-source to hedge risk. For the rest of the top 50—Brazil, India, Mexico, Indonesia, Turkey, Russia, Australia, Canada, South Korea, Spain, Saudi Arabia, Argentina, South Africa, Thailand, Poland, Malaysia, UAE, Netherlands, Switzerland, Egypt, Norway, Israel, Ireland, Denmark, Singapore, the Philippines, Colombia, Bangladesh, Vietnam, Chile, Romania, Czech Republic, Portugal, New Zealand, Finland, Hungary, Slovakia, Greece—the pattern repeats but on a smaller scale: national health leaders want reliability, flexibility in shipping, and a price per kilo that beats last quarter’s budget. China, blending aggressive pricing, rising tech skill, and huge production, now sits alongside the traditional olive heartlands. I’d put my money on more price competitiveness coming from scale in China and Turkey, while product differentiation and small-batch quality continue from Italy, Greece, and Spain.
Chengguan District, Lanzhou, Gansu, China
